TY - JOUR
T1 - Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype
AU - Kalb, Reinhard
AU - Neveling, Kornelia
AU - Hoehn, Holger
AU - Schneider, Hildegard
AU - Linka, Yvonne
AU - Batish, Sat Dev
AU - Hunt, Curtis
AU - Berwick, Marianne
AU - Callén, Elsa
AU - Surrallés, Jordi
AU - Casado, José A.
AU - Bueren, Juan
AU - Dasí, Ángeles
AU - Soulier, Jean
AU - Gluckman, Eliane
AU - Zwaan, C. Michel
AU - Van Spaendonk, Rosalina
AU - Pals, Gerard
AU - De Winter, Johan P.
AU - Joenje, Hans
AU - Grompe, Markus
AU - Auerbach, Arleen D.
AU - Hanenberg, Helmut
AU - Schindler, Detlev
N1 - Funding Information:
We thank Richard Friedl (Wurzburg), for expert flow cytometry; Birgit Gottwald (Wurzburg), for dedicated cell culture work; Daniela Endt (Wurzburg), for sequencing; Dr. Sabine Herterich (Wurzburg), for microsatellite analyses; and Kerstin Goettsche and Silke Furlan (Dusseldorf), for assistance with retroviral vectors. We are grateful to Dr. Heidemarie Neitzel (Berlin), for providing patient DNAs, and to Ralf Dietrich (Unna), for facilitating personal contacts with FA-affected families and for arranging for insight into their medical histories. The GR plasmid for construction of diagnostic retroviral vectors was kindly provided by Dr. Christopher Baum (Hamburg). We thank Dr. Birgit Pils (Oxford, United Kingdom), for help with database searches; Dr. Heiner Schaal (Dusseldorf), Dr. Adrian Krainer (Cold Spring Harbor, NY), and Dr. Chris Smith (Cambridge, United Kingdom), for advice with the characterization of some of the splice-site mutations. Dr. Markus Schmugge (Zurich) and Dr. Eva Seemanova (Prague) are gratefully acknowledged for providing clinical information, as are Drs. John Wagner (Minneapolis), David Williams (Cincinnati), Farid Boulad (New York), and many other physicians who provided clinical data for the IFAR. We are deeply obliged to all of the participating patients and families and to the many clinicians who contributed to the present work through their patient care. This work was supported in part by grants from the Deutsche Fanconi-Anämie-Hilfe (to H. Hoehn and D.S.), the Schroeder-Kurth Fund (to R.K. and D.S.), and the Senator Kurt und Inge Schuster Foundation (to R.K.) and by National Institutes of Health grants R37 HL32987 (to A.D.A.) and R01 CA82678 (to M.B. and A.D.A.). The work of J.S. was funded by European Union grant FI6R-CT-2003-508842; Spanish Ministries of Science grant SAF2006-03340; Spanish Ministries of Health grants PI051205, G03/073, and PI061099; and the La Caixa Foundation Oncology Programme. The Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas has been supported by Spanish Ministry of Health grant G03/073; VI Framework Program of the E.U. grant CONSERT, Ref. 005242; and Spanish Interministerial Commission for Science and Technology grant SAF 2005-00058). J.P.d.W., H.J., and H. Hanenberg were supported by the Fanconi Anemia Research Fund; J.P.d.W. and H.J. were supported by the Dutch Cancer Society.
PY - 2007/5
Y1 - 2007/5
N2 - FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a key role in DNA double-strand-type damage responses. Using complementation assays and immunoblotting, a consortium of American and European groups assigned 29 patients with FA from 23 families and 4 additional unrelated patients to complementation group FA-D2. This amounts to 3%-6% of FA-affected patients registered in various data sets. Malformations are frequent in FA-D2 patients, and hematological manifestations appear earlier and progress more rapidly when compared with all other patients combined (FA-non-D2) in the International Fanconi Anemia Registry. FANCD2 is flanked by two pseudogenes. Mutation analysis revealed the expected total of 66 mutated alleles, 34 of which result in aberrant splicing patterns. Many mutations are recurrent and have ethnic associations and shared allelic haplotypes. There were no biallelic null mutations; residual FANCD2 protein of both isotypes was observed in all available patient cell lines. These analyses suggest that, unlike the knockout mouse model, total absence of FANCD2 does not exist in FA-D2 patients, because of constraints on viable combinations of FANCD2 mutations. Although hypomorphic mutations arie involved, clinically, these patients have a relatively severe form of FA.
AB - FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a key role in DNA double-strand-type damage responses. Using complementation assays and immunoblotting, a consortium of American and European groups assigned 29 patients with FA from 23 families and 4 additional unrelated patients to complementation group FA-D2. This amounts to 3%-6% of FA-affected patients registered in various data sets. Malformations are frequent in FA-D2 patients, and hematological manifestations appear earlier and progress more rapidly when compared with all other patients combined (FA-non-D2) in the International Fanconi Anemia Registry. FANCD2 is flanked by two pseudogenes. Mutation analysis revealed the expected total of 66 mutated alleles, 34 of which result in aberrant splicing patterns. Many mutations are recurrent and have ethnic associations and shared allelic haplotypes. There were no biallelic null mutations; residual FANCD2 protein of both isotypes was observed in all available patient cell lines. These analyses suggest that, unlike the knockout mouse model, total absence of FANCD2 does not exist in FA-D2 patients, because of constraints on viable combinations of FANCD2 mutations. Although hypomorphic mutations arie involved, clinically, these patients have a relatively severe form of FA.
UR - http://www.scopus.com/inward/record.url?scp=34247576595&partnerID=8YFLogxK
U2 - 10.1086/517616
DO - 10.1086/517616
M3 - Article
AN - SCOPUS:34247576595
SN - 0002-9297
VL - 80
SP - 895
EP - 910
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 5
ER -